Raloxifene therapy in postmenopausal women is associated with a significant reduction in the concentration of serum vascular endothelial growth factor.
D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000706:statistics & numerical data; D008875:Middle Aged; D010919:Placebos; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D015415:Biomarkers; D004965:Estrogen Antagonists; D010919:Placebos; D042461:Vascular Endothelial Growth Factor A; D020849:Raloxifene Hydrochloride